MRI vastus lateralis fat fraction predicts loss of ambulation in Duchenne muscular dystrophy
Authors:
- Karin J. NaardingKNKarin J. Naarding
- Harmen ReyngoudtHRHarmen Reyngoudt
- Erik W. van ZwetEZErik W. van Zwet
- Melissa T. HooijmansMHMelissa T. Hooijmans
- Cuixia TianCTCuixia Tian
- Irina RybalskyIRIrina Rybalsky
- Karen C. ShellenbargerKSKaren C. Shellenbarger
- Julien Le LouërJLJulien Le Louër
- Brenda L. WongBWBrenda L. Wong
- Pierre G. CarlierPCPierre G. Carlier
- Hermien E. KanHKHermien E. Kan
- Erik H. NiksENErik H. Niks
Open Access
- 14 January 2020
- journal article
- research article
- Published by Wolters Kluwer Health in Neurology
- Vol. 94 (13) , e1386-e1394
Abstract
Objective We studied the potential of quantitative MRI (qMRI) as a surrogate endpoint in Duchenne muscular dystrophy by assessing the additive predictive value of vastus lateralis (VL) fat fraction (FF) to age on loss of ambulation (LoA). Methods VL FFs were determined on longitudinal Dixon MRI scans from 2 natural history studies in Leiden University Medical Center (LUMC) and Cincinnati Children9s Hospital Medical Center (CCHMC). CCHMC included ambulant patients, while LUMC included a mixed ambulant and nonambulant population. We fitted longitudinal VL FF values to a sigmoidal curve using a mixed model with random slope to predict individual trajectories. The additive value of VL FF over age to predict LoA was calculated from a Cox model, yielding a hazard ratio. Results Eighty-nine MRIs of 19 LUMC and 15 CCHMC patients were included. At similar age, 6-minute walking test distances were smaller and VL FFs were correspondingly higher in LUMC compared to CCHMC patients. Hazard ratio of a percent-point increase in VL FF for the time to LoA was 1.15 for LUMC (95% confidence interval [CI] 1.05–1.26; p = 0.003) and 0.96 for CCHMC (95% CI 0.84–1.10; p = 0.569). Conclusions The hazard ratio of 1.15 corresponds to a 4.11-fold increase of the instantaneous risk of LoA in patients with a 10% higher VL FF at any age. Although results should be confirmed in a larger cohort with prospective determination of the clinical endpoint, this added predictive value of VL FF to age on LoA supports the use of qMRI FF as an endpoint or stratification tool in clinical trials.Keywords
This publication has 41 references indexed in Scilit:
- Reliability of the Performance of Upper Limb assessment in Duchenne muscular dystrophyNeuromuscular Disorders, 2014
- 6 Minute Walk Test in Duchenne MD Patients with Different Mutations: 12 Month ChangesPLOS ONE, 2014
- Skeletal Muscles of Ambulant Children with Duchenne Muscular Dystrophy: Validation of Multicenter Study of Evaluation with MR Imaging and MR SpectroscopyRadiology, 2013
- THE 6‐minute walk test and other endpoints in Duchenne muscular dystrophy: Longitudinal natural history observations over 48 weeks from a multicenter studyMuscle & Nerve, 2013
- The world’s tallest nation has stopped growing taller: the height of Dutch children from 1955 to 2009Pediatric Research, 2012
- Quantitative MRI and loss of free ambulation in Duchenne muscular dystrophyJournal of Neurology, 2012
- Relationships of thigh muscle contractile and non-contractile tissue with function, strength, and age in boys with Duchenne muscular dystrophyNeuromuscular Disorders, 2012
- Muscle fat-fraction and mapping in Duchenne muscular dystrophy: evaluation of disease distribution and correlation with clinical assessmentsSkeletal Radiology, 2011
- Musculoskeletal MRI at 3.0 T: Relaxation Times and Image ContrastAmerican Journal of Roentgenology, 2004
- Muscle hypertrophy in Duchenne muscular dystrophyJournal of Neurology, 1989